Presti, Mario http://orcid.org/0000-0001-5984-1793
Westergaard, Marie Christine Wulff http://orcid.org/0000-0003-3446-4287
Draghi, Arianna http://orcid.org/0000-0002-5894-6750
Chamberlain, Christopher Aled http://orcid.org/0000-0002-9574-2466
Gokuldass, Aishwarya
Svane, Inge Marie http://orcid.org/0000-0002-9451-6037
Donia, Marco http://orcid.org/0000-0003-4966-9752
Funding for this research was provided by:
Kræftens Bekæmpelse (R184-A11806)
Kræftens Bekæmpelse (Empowering Cancer Immunotherapy in Denmark)
Article History
Received: 18 July 2020
Accepted: 15 October 2020
First Online: 9 November 2020
Compliance with ethical standards
:
: Marco Donia has received honoraria for lectures from Roche and Novartis (past 2 years); Inge Marie Svane has received honoraria for consultancies and lectures from Novartis, Roche, Merck, and Bristol-Myers Squibb; a restricted research grant from Novartis; and financial support for attending symposia from Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche. All other authors declare that they have no conflict of interest.